id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-D-5255-0002,FDA,FDA-2019-D-5255,Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2019-11-29T05:00:00Z,2019,11,2019-11-29T05:00:00Z,2020-01-29T04:59:59Z,2020-01-29T02:08:15Z,2019-25919,0,0,09000064841c88a5
FDA-2019-D-5255-0001,FDA,FDA-2019-D-5255,Clinical Immunogenicity Considerations for Biosimilar and Interchangeable  Insulin Products; Guidance for Industry; Draft Guidance,Other,Guidance,2019-11-26T05:00:00Z,2019,11,2019-11-26T05:00:00Z,,2024-11-12T23:13:15Z,,1,0,09000064841b8154